Point72 (DIFC)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Point72 (DIFC)’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,071	Closed	-$12.4K	–	2157
2024 Q4	$12.4K	Buy	4,071 +2,372	+140%	+$10.3K	﹤0.01%	1319
2024 Q3	$8.82K	Buy	+1,699	New	+$8.44K	﹤0.01%	1274

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Point72 (DIFC)'s RVNC Position: Q1 2025 in Review

Point72 (DIFC) sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 4,071 shares — an estimated $12.4K sold.

Point72 (DIFC) first reported a position in RVNC in Q3 2024 and held it in 2 quarters. The position peaked at $12.4K in Q4 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Point72 (DIFC) reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Point72 (DIFC) sold 4,071 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $12.4K.
Point72 (DIFC) first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 2 quarters.
Point72 (DIFC)'s Revance Therapeutics, Inc. position peaked at $12.4K in Q4 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.